JP5188807B2 - ｍＧｌｕＲ３受容体アンタゴニストとして用いるための１−（ヘテロ）アリール−３−アミノ−ピロリジン誘導体 - Google Patents

ｍＧｌｕＲ３受容体アンタゴニストとして用いるための１−（ヘテロ）アリール−３−アミノ−ピロリジン誘導体 Download PDF

Info

Publication number
JP5188807B2
JP5188807B2 JP2007536836A JP2007536836A JP5188807B2 JP 5188807 B2 JP5188807 B2 JP 5188807B2 JP 2007536836 A JP2007536836 A JP 2007536836A JP 2007536836 A JP2007536836 A JP 2007536836A JP 5188807 B2 JP5188807 B2 JP 5188807B2
Authority
JP
Japan
Prior art keywords
mmol
pyrrolidin
compound
group
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007536836A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008516959A (ja
JP2008516959A5 (enExample
Inventor
トーマス・チャールズ・ブリットン
ヴェロニク・デリンジェ
コリン・ピーター・デル
ブルース・アンソニー・ドレスマン
ジェイソン・ケネス・マイヤーズ
エリック・サミュエル・ニセンバウム
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2008516959A publication Critical patent/JP2008516959A/ja
Publication of JP2008516959A5 publication Critical patent/JP2008516959A5/ja
Application granted granted Critical
Publication of JP5188807B2 publication Critical patent/JP5188807B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/41—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by hydrogenolysis or reduction of carboxylic groups or functional derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
JP2007536836A 2004-10-18 2005-10-13 ｍＧｌｕＲ３受容体アンタゴニストとして用いるための１−（ヘテロ）アリール−３−アミノ−ピロリジン誘導体 Expired - Fee Related JP5188807B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61978904P 2004-10-18 2004-10-18
US60/619,789 2004-10-18
PCT/US2005/036665 WO2006044454A1 (en) 2004-10-18 2005-10-13 1-(hetero)aryl-3-amino-pyrollidine derivatives for use as mglur3 receptor antagonists

Publications (3)

Publication Number Publication Date
JP2008516959A JP2008516959A (ja) 2008-05-22
JP2008516959A5 JP2008516959A5 (enExample) 2008-11-06
JP5188807B2 true JP5188807B2 (ja) 2013-04-24

Family

ID=35787981

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007536836A Expired - Fee Related JP5188807B2 (ja) 2004-10-18 2005-10-13 ｍＧｌｕＲ３受容体アンタゴニストとして用いるための１−（ヘテロ）アリール−３−アミノ−ピロリジン誘導体

Country Status (12)

Country Link
US (1) US7868014B2 (enExample)
EP (1) EP1805165B1 (enExample)
JP (1) JP5188807B2 (enExample)
CN (1) CN101094846A (enExample)
AT (1) ATE452130T1 (enExample)
AU (1) AU2005295860A1 (enExample)
BR (1) BRPI0516602A (enExample)
CA (1) CA2584422A1 (enExample)
DE (1) DE602005018381D1 (enExample)
ES (1) ES2336130T3 (enExample)
MX (1) MX2007004661A (enExample)
WO (1) WO2006044454A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1757582T3 (pl) 2004-05-28 2016-04-29 Mitsubishi Tanabe Pharma Corp Aryloalkiloaminy i sposób ich wytwarzania
FR2928150A1 (fr) 2008-02-29 2009-09-04 Vetoquinol Sa Sa Nouveaux derives 7-substitues de 3-carboxy-oxadiazino-quinolones, leur preparation et leur application comme anti-bacteriens
WO2009131196A1 (ja) * 2008-04-24 2009-10-29 武田薬品工業株式会社 置換ピロリジン誘導体およびその用途
EP2145891A1 (en) 2008-07-09 2010-01-20 Vetoquinol S.A. 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials
TW201022233A (en) * 2008-11-04 2010-06-16 Organon Nv (Pyrrolidin-2-yl)phenyl derivatives
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
JP6678672B2 (ja) * 2014-12-11 2020-04-08 ヤンセン ファーマシューティカ エヌ．ベー． １，２，４−トリアゾロ［４，３−ａ］ピリジン化合物およびＭＧＬＵＲ２受容体の正のアロステリック調節因子としてのその使用
CN113024412A (zh) * 2021-03-23 2021-06-25 上海立科化学科技有限公司 2,4,6-三氯苯腈的制备方法
CN114149297A (zh) * 2021-12-07 2022-03-08 北京中医药大学 一种微波辅助的选择性芳基甲醛的绿色合成方法
CN115368283A (zh) * 2022-09-15 2022-11-22 丽水绿氟科技有限公司 一种手性结构或非手性结构的顺式-3-氟-4-羟基吡咯烷及其衍生物的制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001125A (en) * 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
US4785119A (en) * 1985-10-11 1988-11-15 Tokyo Kasei Kogyo Co., Ltd. 3-aminopyrrolidine compound and process for preparation thereof
UA41251C2 (uk) 1990-01-04 2001-09-17 Пфайзер, Інк. Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
US5332817A (en) * 1990-01-04 1994-07-26 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
TW202432B (enExample) * 1991-06-21 1993-03-21 Pfizer
WO1995029891A1 (en) * 1994-04-28 1995-11-09 Yamanouchi Pharmaceutical Co., Ltd. N-(3-pyrrolidinyl)benzamide derivative
ES2079323B1 (es) * 1994-06-21 1996-10-16 Vita Invest Sa Derivados de indol utiles para el tratamiento de la migraña, composicion y uso correspondientes.
DE19524765A1 (de) * 1995-07-07 1997-01-09 Boehringer Mannheim Gmbh Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
JP2001521484A (ja) 1996-01-22 2001-11-06 イーライ・リリー・アンド・カンパニー 置換されたインダンのライブラリーを製造するための組み合わせ方法
US6313127B1 (en) 1996-02-02 2001-11-06 Zeneca Limited Heterocyclic compounds useful as pharmaceutical agents
US5891889A (en) * 1996-04-03 1999-04-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2001515839A (ja) * 1997-07-18 2001-09-25 ジョージタウン・ユニバーシティ 二環式向代謝性グルタミン酸受容体リガンド
CA2297906A1 (en) 1997-07-22 1999-02-04 Bret Eugene Huff Pharmaceutical compounds
US20010006972A1 (en) 1998-04-21 2001-07-05 Stephen A. Williams Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
WO1999064396A1 (en) * 1998-06-09 1999-12-16 Neurogen Corporation Substituted 1-aryl-3-benzylaminopyrrolidine: dopamine receptor subtype specific ligands
AU2002342414A1 (en) 2001-05-10 2002-11-25 Aventis Pharma Deutschland Gmbh Novel processes for the preparation of adenosine compounds and intermediates thereto
US7521062B2 (en) * 2002-12-27 2009-04-21 Novartis Vaccines & Diagnostics, Inc. Thiosemicarbazones as anti-virals and immunopotentiators
DE10306250A1 (de) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PL1638933T3 (pl) 2003-06-17 2008-10-31 Pfizer Pochodne n-pirolidyn-3-yloamidu jako inhibitory wychwytu zwrotnego serotoniny i noradrenaliny
US7348434B2 (en) * 2003-08-08 2008-03-25 Antony Bigot 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them
BRPI0414909A (pt) * 2003-10-31 2006-11-07 Otsuka Pharma Co Ltd composto, agente antituberculoso, e, método para produzir um composto
PL1757582T3 (pl) 2004-05-28 2016-04-29 Mitsubishi Tanabe Pharma Corp Aryloalkiloaminy i sposób ich wytwarzania

Also Published As

Publication number Publication date
US7868014B2 (en) 2011-01-11
DE602005018381D1 (de) 2010-01-28
WO2006044454A1 (en) 2006-04-27
JP2008516959A (ja) 2008-05-22
EP1805165A1 (en) 2007-07-11
CN101094846A (zh) 2007-12-26
AU2005295860A1 (en) 2006-04-27
BRPI0516602A (pt) 2008-09-16
ATE452130T1 (de) 2010-01-15
CA2584422A1 (en) 2006-04-27
ES2336130T3 (es) 2010-04-08
EP1805165B1 (en) 2009-12-16
MX2007004661A (es) 2007-06-22
US20080300266A1 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
TWI796205B (zh) 新穎cyp11a1抑制劑
CA2280753C (en) 1,4-substituted cyclic amine derivatives
CA2770932C (en) Substituted n-phenyl-1-(4-pyridinyl)-1h-pyrazol-3-amines
WO2013170072A2 (en) Compounds for the treatment of neurological disorders
AU2008240728B2 (en) 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists
EP2678315B1 (en) (Pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nAChR
JP2011507868A (ja) 鉱質コルチコイド受容体アンタゴニストおよび使用方法
CA2617654A1 (en) Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
JP5188807B2 (ja) ｍＧｌｕＲ３受容体アンタゴニストとして用いるための１−（ヘテロ）アリール−３−アミノ−ピロリジン誘導体
KR20150074154A (ko) 도파민 d3 수용체의 조절에 반응하는 장애의 치료에 적합한 아실아미노사이클로알킬 화합물
KR20090089858A (ko) 피페리디닐아미노-피리다진 및 속해리성 도파민 ２ 수용체 길항제로서의 그의 용도
AU2008240727B2 (en) Pyridine derivatives as fast dissociating dopamine 2 receptor antagonists
WO2009145721A1 (en) Isoindoline derivatives comprising phenyl groups and their use in the treatment of pain disorders
CA2849385A1 (en) 2-oxo-piperidinyl derivatives
JP2018533551A (ja) 治療用化合物及びその使用方法
WO2009050186A1 (en) Trisubstituted 1,2,4-triazoles
CN101365678A (zh) 可用于治疗h3受体相关病症的h3受体调节剂
CN120398798A (zh) 钠通道调节剂新化合物及其应用
HK1139674A (en) Pyridine derivatives as fast dissociating dopamine 2 receptor antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130123

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160201

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees